Heart HealthResearch PaperOpen Access

Everolimus Pulls VE-Cadherin Off Blood Vessel Cell Junctions Through Endocytosis and Lysosomal Breakdown

In cultured human endothelial cells, everolimus drove VE-cadherin into endocytic and lysosomal pathways and weakened the barrier. Blocking those routes preserved junctions.

Wednesday, November 18, 2026 1 view
Published in Cell Mol Bioeng
confocal microscope in a lab with a petri dish of cultured endothelial cells and a monitor showing fluorescent cell borders

Summary

Everolimus, a rapamycin analog used in transplant medicine and drug-eluting stents, is associated with edema in transplant recipients; delayed endothelial healing has also been reported in an everolimus-eluting stent model. This cell study examined a mechanism. In cultured human umbilical vein endothelial cells treated with 500 nM everolimus for 4 or 24 hours, continuous VE-cadherin junctions decreased and punctate junctions increased. Pharmacologic experiments supported clathrin-mediated internalization and lysosomal degradation: blocking either pathway preserved VE-cadherin continuity, while disrupting Golgi trafficking blocked partial junctional recovery. Actin organization also changed, electrical resistance fell, and dextran permeability rose 2.24–2.63-fold. These cell-culture findings identify a vascular mechanism relevant to rapalog research, but do not establish clinical risk at longevity-use exposures or effects on healthspan or lifespan.

Detailed Summary

Rapamycin and its analogs draw longevity interest through mTOR inhibition, making their effects on the vessel lining relevant to rapalog-based strategies. The source cites clinical associations between everolimus and edema in transplant recipients, and delayed endothelial healing in an in vivo model of everolimus-eluting stents. This study examined the underlying cellular mechanism in vitro.

The team treated primary human umbilical vein endothelial cells (HUVECs) with 500 nM everolimus for 4 or 24 hours. They used confocal microscopy and JAnaP software to classify VE-cadherin junctions as continuous, punctate or perpendicular. For junction analysis, approximately 10–20 cells per image and 4–6 images per condition were evaluated for each of at least three independent biological replicates. The supplied excerpt does not specify donor counts or exact total cells per condition. Human brain microvascular endothelial cells were included in supplemental experiments, but their results are not provided here.

The abstract reports that everolimus reduced continuous VE-cadherin and increased punctate junctions, with partially reversible junctional disruption. The supplied material does not provide the numerical junction percentages or recovery statistics.

Mechanistically, chlorpromazine, used to inhibit clathrin-mediated endocytosis, and chloroquine, used to inhibit lysosomal degradation, preserved VE-cadherin continuity. Brefeldin A, which disrupts Golgi trafficking, blocked recovery. These findings support a model in which internalization and lysosomal degradation disrupt junctions while Golgi-dependent trafficking contributes to partial restoration. The inhibitors have limited specificity, so their broader cellular effects constrain pathway attribution. Brefeldin A exposure was limited to acute 4-hour periods because overnight treatment caused cytotoxicity.

Everolimus also increased F-actin anisotropy: stress fibers became more aligned within individual cells, while intracellular organization was transiently uncoupled from coordinated alignment across the monolayer. Functionally, transendothelial electrical resistance fell and 4 kDa FITC-dextran permeability rose 2.24–2.63-fold. Partial junctional restoration therefore should not be equated with demonstrated restoration of barrier function. These outcomes are reported in the abstract; the supplied excerpt ends during the methods and does not include the detailed Results section.

The study connects VE-cadherin trafficking and actin remodeling to measurable endothelial barrier dysfunction in cultured human cells. It does not establish whether the same effects occur in patients at clinical exposures, whether lower or intermittent rapalog dosing avoids them, or whether targeting these pathways can safely protect vessels in vivo. The tested everolimus concentration was 500 nM, with 4- and 24-hour exposure periods; healthspan and lifespan were not assessed.

Key Findings

  • In cultured HUVECs treated with 500 nM everolimus for 4 or 24 hours, continuous VE-cadherin decreased and punctate junctions increased.
  • Junctional disruption was partially reversible, but the supplied excerpt does not provide numerical junction percentages or recovery statistics.
  • Pharmacologic inhibition of clathrin-mediated endocytosis with chlorpromazine or lysosomal degradation with chloroquine preserved VE-cadherin continuity; inhibitor specificity was limited.
  • Golgi disruption with brefeldin A blocked junctional recovery, supporting a role for Golgi-dependent trafficking in partial restoration.
  • Everolimus increased F-actin anisotropy within individual cells while transiently uncoupling intracellular actin organization from coordinated alignment across the monolayer.
  • Barrier function worsened in HUVEC monolayers: TEER fell and 4 kDa FITC-dextran permeability rose 2.24–2.63-fold.
  • Supplemental brain microvascular endothelial-cell experiments were included, but their results are absent from the supplied excerpt. This study provides cell-culture mechanism and barrier-function evidence, not in vivo or lifespan outcomes.

Methodology

Controlled in vitro study using primary HUVECs at passages 4–6, with supplemental HBMEC experiments at passages 7–10. Everolimus was applied at 500 nM for 4 or 24 hours. Confocal microscopy and JAnaP classified VE-cadherin junctions as continuous, perpendicular or punctate. Junction analysis included approximately 10–20 cells per image and 4–6 images per condition for each of at least three independent biological replicates. Donor counts, exact total cell counts, statistical tests and handling of nested cell-level observations are not available in the supplied excerpt. The abstract reports F-actin anisotropy, TEER and 4 kDa FITC-dextran permeability measurements. Pharmacologic inhibitors had limited specificity; brefeldin A exposure was limited to acute 4-hour periods because overnight exposure caused cytotoxicity.

Study Limitations

Cultured endothelial cells treated with a single everolimus concentration of 500 nM for 4 or 24 hours cannot establish effects in living vessels, clinical risk at patient exposures, or responses to lower or intermittent dosing. Pharmacologic inhibitors have limited specificity, and overnight brefeldin A treatment caused cytotoxicity. The supplied excerpt lacks donor counts, exact total cell counts, detailed results and statistical methods, preventing assessment of how cell-level observations were handled. It also does not provide the supplemental HBMEC outcomes. Healthspan and lifespan were not assessed. No conflict-of-interest statement is included in the supplied text.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: